$BIOLQ
BIOLASE, INC

2015 Q1 Form 10-Q Financial Statement

#000156459015003181 Filed on May 01, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q1
Revenue $10.86M $11.52M
YoY Change -5.76% -21.09%
Cost Of Revenue $7.645M $7.577M
YoY Change 0.9% -13.93%
Gross Profit $3.210M $3.941M
YoY Change -18.55% -31.98%
Gross Profit Margin 29.57% 34.22%
Selling, General & Admin $7.341M $7.538M
YoY Change -2.61% 0.52%
% of Gross Profit 228.69% 191.27%
Research & Development $1.803M $973.0K
YoY Change 85.3% -3.18%
% of Gross Profit 56.17% 24.69%
Depreciation & Amortization $158.0K $175.0K
YoY Change -9.71% 20.69%
% of Gross Profit 4.92% 4.44%
Operating Expenses $8.469M $8.576M
YoY Change -1.25% -0.41%
Operating Profit -$5.259M -$4.635M
YoY Change 13.46% 64.54%
Interest Expense -$130.0K -$230.0K
YoY Change -43.48% 164.37%
% of Operating Profit
Other Income/Expense, Net -$130.0K -$228.0K
YoY Change -42.98% 22.58%
Pretax Income -$5.389M -$4.863M
YoY Change 10.82% 61.94%
Income Tax $47.00K $24.00K
% Of Pretax Income
Net Earnings -$5.436M -$4.887M
YoY Change 11.23% 85.75%
Net Earnings / Revenue -50.08% -42.43%
Basic Earnings Per Share -$0.09 -$0.13
Diluted Earnings Per Share -$0.09 -$0.13
COMMON SHARES
Basic Shares Outstanding 58.15M 36.46M
Diluted Shares Outstanding 58.15M 36.46M

Balance Sheet

Concept 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.74M $1.840M
YoY Change 1190.22% 49.59%
Cash & Equivalents $23.74M $1.835M
Short-Term Investments
Other Short-Term Assets $2.250M $1.290M
YoY Change 74.42% -21.34%
Inventory $13.17M $11.89M
Prepaid Expenses
Receivables $9.810M $8.560M
Other Receivables $0.00 $0.00
Total Short-Term Assets $48.97M $23.57M
YoY Change 107.76% -7.32%
LONG-TERM ASSETS
Property, Plant & Equipment $1.750M $1.750M
YoY Change 0.0% 8.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $960.0K $247.0K
YoY Change 288.66% -12.41%
Total Long-Term Assets $5.720M $5.087M
YoY Change 12.44% -0.12%
TOTAL ASSETS
Total Short-Term Assets $48.97M $23.57M
Total Long-Term Assets $5.720M $5.087M
Total Assets $54.69M $28.66M
YoY Change 90.84% -6.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.650M $7.776M
YoY Change -1.62% -10.7%
Accrued Expenses $4.870M $4.941M
YoY Change -1.44% 1.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $2.880M
YoY Change -100.0% -11.66%
Long-Term Debt Due $140.0K
YoY Change
Total Short-Term Liabilities $15.76M $19.02M
YoY Change -17.14% -6.11%
LONG-TERM LIABILITIES
Long-Term Debt $240.0K $0.00
YoY Change
Other Long-Term Liabilities $870.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $1.110M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.76M $19.02M
Total Long-Term Liabilities $1.110M $0.00
Total Liabilities $17.57M $19.65M
YoY Change -10.59% -5.73%
SHAREHOLDERS EQUITY
Retained Earnings -$128.6M
YoY Change 11.96%
Common Stock $186.0M $40.00K
YoY Change 464830.0% 17.65%
Preferred Stock
YoY Change
Treasury Stock (at cost) $16.40M
YoY Change 0.0%
Treasury Stock Shares $1.964M
Shareholders Equity $37.13M $9.005M
YoY Change
Total Liabilities & Shareholders Equity $54.69M $28.66M
YoY Change 90.86% -6.12%

Cashflow Statement

Concept 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$5.436M -$4.887M
YoY Change 11.23% 85.75%
Depreciation, Depletion And Amortization $158.0K $175.0K
YoY Change -9.71% 20.69%
Cash From Operating Activities -$7.400M -$2.800M
YoY Change 164.29% -0.78%
INVESTING ACTIVITIES
Capital Expenditures $228.0K $86.00K
YoY Change 165.12% -38.13%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$230.0K -$90.00K
YoY Change 155.56% -39.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.800M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 3.280M
YoY Change -100.0% 92.94%
NET CHANGE
Cash From Operating Activities -7.400M -2.800M
Cash From Investing Activities -230.0K -90.00K
Cash From Financing Activities 0.000 3.280M
Net Change In Cash -7.630M 390.0K
YoY Change -2056.41% -130.68%
FREE CASH FLOW
Cash From Operating Activities -$7.400M -$2.800M
Capital Expenditures $228.0K $86.00K
Free Cash Flow -$7.628M -$2.886M
YoY Change 164.31% -2.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1295000
CY2014Q4 us-gaap Inventory Net
InventoryNet
12508000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1726000
CY2014Q1 us-gaap Sales Revenue Net
SalesRevenueNet
11518000
CY2014Q1 us-gaap Cost Of Revenue
CostOfRevenue
7577000
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58115000
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
114000
CY2015Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
200000
CY2015Q1 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
240000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9004000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
54798000
CY2014Q4 us-gaap Goodwill
Goodwill
2926000
CY2014Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
519000
CY2014Q1 us-gaap Gross Profit
GrossProfit
3941000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
973000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000
CY2014Q1 biol Products And Services Revenue
ProductsAndServicesRevenue
11479000
CY2014Q1 biol License Fees And Royalty Revenue
LicenseFeesAndRoyaltyRevenue
39000
CY2014Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4455000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3083000
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-228000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-4887000
CY2015Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-233000
CY2014Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36455000
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36455000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5259000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
8469000
CY2015Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-130000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-130000
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
47000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4886000
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58145000
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58145000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
158000
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
175000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5669000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
700000
CY2014Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2000
CY2014Q1 us-gaap Interest And Debt Expense
InterestAndDebtExpense
230000
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5389000
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4863000
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
24000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-5436000
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2014Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
CY2015Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
53000
CY2014Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
268000
CY2014Q1 us-gaap Inventory Write Down
InventoryWriteDown
261000
CY2014Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
120000
CY2014Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
57000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
310000
CY2014Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-61000
CY2015Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
15000
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
185972000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
37128000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54694000
CY2015Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1764000
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58153000
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58153000
CY2015Q1 biol Products And Services Revenue
ProductsAndServicesRevenue
10751000
CY2015Q1 biol License Fees And Royalty Revenue
LicenseFeesAndRoyaltyRevenue
104000
CY2015Q1 us-gaap Sales Revenue Net
SalesRevenueNet
10855000
CY2015Q1 us-gaap Cost Of Revenue
CostOfRevenue
7645000
CY2015Q1 us-gaap Gross Profit
GrossProfit
3210000
CY2015Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4754000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2587000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1803000
CY2015Q1 biol Excise Tax
ExciseTax
56000
CY2014Q1 biol Excise Tax
ExciseTax
65000
CY2015Q1 biol Litigation Expense Recovered
LitigationExpenseRecovered
731000
CY2014Q1 biol Litigation Expense Recovered
LitigationExpenseRecovered
0
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
8576000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4635000
CY2014Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
15000
CY2014Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
12000
CY2015Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
200000
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
860000
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2301000
CY2015Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
664000
CY2014Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
774000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
677000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2000
CY2015Q1 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
64000
CY2014Q1 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
-135000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1090000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-392000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
535000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-190000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7402000
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2797000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
228000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
86000
CY2014Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-228000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-85000
CY2014Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
7570000
CY2014Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
9325000
CY2014Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
10000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4793000
CY2015Q1 biol Deposit On Capital Lease
DepositOnCapitalLease
42000
CY2015Q1 biol Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
44000
CY2014Q1 biol Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
248000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3276000
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-193000
CY2014Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
1000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7821000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
395000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1440000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1835000
CY2014Q1 us-gaap Interest Paid
InterestPaid
67000
CY2015Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
37000
CY2014Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
5000
CY2015Q1 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
383000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8990
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0178
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5000000
CY2014Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2857000
CY2015Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1528000
CY2014Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1348000
CY2015Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
8693000
CY2014Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
8303000
CY2015Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2400000
CY2014Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2400000
CY2015Q1 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
7386000
CY2014Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
6788000
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5796000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5669000
CY2015Q1 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
1590000
CY2014Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
1119000
CY2015Q1 us-gaap Land
Land
157000
CY2014Q4 us-gaap Land
Land
176000
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
140000
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
157000
CY2015Q1 biol Indefinite Lived Intangible Assets Useful Life
IndefiniteLivedIntangibleAssetsUsefulLife
Indefinite life
CY2015Q1 us-gaap Goodwill Gross
GoodwillGross
2926000
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2177000
CY2015Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1027000
CY2015Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
38000
CY2014Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
139000
CY2015Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1566000
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, indefinite-lived intangible assets, and the ability of goodwill to be realized, revenue deferrals for multiple element arrangements, effects of stock-based compensation and warrants, contingent liabilities, and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates. </p></div>
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
310000
CY2015Q1 biol Share Based Compensation Net Impact On Earning Per Share Basic
ShareBasedCompensationNetImpactOnEarningPerShareBasic
-0.01
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
153000
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y4M24D
CY2015Q1 us-gaap Extended Product Warranty Accrual Current
ExtendedProductWarrantyAccrualCurrent
1505000
CY2014Q1 biol Share Based Compensation Net Impact On Earning Per Share Basic
ShareBasedCompensationNetImpactOnEarningPerShareBasic
-0.01
CY2015Q1 biol Share Based Compensation Net Impact On Earning Per Share Diluted
ShareBasedCompensationNetImpactOnEarningPerShareDiluted
-0.01
CY2014Q1 biol Share Based Compensation Net Impact On Earning Per Share Diluted
ShareBasedCompensationNetImpactOnEarningPerShareDiluted
-0.01
CY2015Q1 biol Working Capital
WorkingCapital
33200000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
700000
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y2M12D
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y7M6D
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9837
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
38000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0165
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3391000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2232000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5432000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2680000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
25000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.11
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.44
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.15
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.44
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.84
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.11
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
3.96
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y11M19D
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y5M16D
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y3M22D
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1063000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
186000
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
183000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
44000
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
248000
CY2015Q1 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
CY2014Q1 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
52000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
82000
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.86
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
293000
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
346000
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15563000
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5998000
CY2014Q1 biol Percentage Of Stock Dividends Payable
PercentageOfStockDividendsPayable
0.0050
CY2014Q1 us-gaap Dividends Payable Date Of Record Day Month And Year
DividendsPayableDateOfRecordDayMonthAndYear
2014-03-14
CY2015Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
2951000
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2015Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
18000
CY2014Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
18000
CY2015Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2800000
CY2015Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2704000
CY2014Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2800000
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2686000
CY2015Q1 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
143000
CY2014Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1025000
CY2013 biol Warranty Period
WarrantyPeriod
P1Y
biol Warranty Period
WarrantyPeriod
P2Y
CY2014Q4 biol Undelivered Elements Training Installation And Product And Support Services
UndeliveredElementsTrainingInstallationAndProductAndSupportServices
952000
CY2014Q4 us-gaap Extended Product Warranty Accrual Current
ExtendedProductWarrantyAccrualCurrent
1542000
CY2015Q1 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
31000
CY2015Q1 biol Number Revolving Credit Facility Agreements
NumberRevolvingCreditFacilityAgreements
2
CY2014Q3 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2900000
CY2014Q1 biol Amendments And Administrative Fees
AmendmentsAndAdministrativeFees
10000
CY2014Q2 biol Amendments And Administrative Fees
AmendmentsAndAdministrativeFees
10000
CY2014Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
5000000
CY2014Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
4000000
CY2014 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2014-05-01
CY2014Q2 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2014-06-01
CY2014Q2 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2014-08-01
CY2014Q2 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2014-08-01
CY2014Q2 biol Line Of Credit Non Compliance Payments
LineOfCreditNonCompliancePayments
10000
CY2014Q2 biol Line Of Credit Non Compliance Payments
LineOfCreditNonCompliancePayments
15000
CY2014Q2 biol Line Of Credit Non Compliance Payments
LineOfCreditNonCompliancePayments
10000
CY2014Q2 us-gaap Debt Instrument Interest Rate Increase Decrease
DebtInstrumentInterestRateIncreaseDecrease
0.0050
CY2015Q1 biol Prime Floor
PrimeFloor
0.0250
CY2014Q1 biol Prime Floor
PrimeFloor
0.0250
CY2015Q1 us-gaap Line Of Credit Facility Unused Capacity Commitment Fee Percentage
LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
0.0025
CY2014Q1 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
229000
CY2014Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
0
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2014Q1 biol Aggregate Amendments And Administrative Fees
AggregateAmendmentsAndAdministrativeFees
10000
CY2015Q1 biol Financed Insurance Premium Payable
FinancedInsurancePremiumPayable
0
CY2014Q1 biol Financed Insurance Premium Payable
FinancedInsurancePremiumPayable
123000
CY2015Q1 us-gaap Short Term Debt Description
ShortTermDebtDescription
Nine
CY2014Q1 biol Financed Insurance Premium Finance Charge
FinancedInsurancePremiumFinanceCharge
0.0285
CY2014Q1 us-gaap Financing Interest Expense
FinancingInterestExpense
1000
CY2015Q1 biol Period For Extended Lease
PeriodForExtendedLease
2020-04-30
CY2015Q1 biol Provisions For Tenant Improvement Allowance Maximum
ProvisionsForTenantImprovementAllowanceMaximum
398000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
483000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
694000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
652000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1500000
CY2015Q1 biol Capital Lease Agreement Lease Term
CapitalLeaseAgreementLeaseTerm
P30M
CY2015Q1 us-gaap Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
129000
CY2015Q1 us-gaap Capital Leases Future Minimum Payments Due In Rolling Year Two
CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo
172000
CY2015Q1 us-gaap Capital Leases Future Minimum Payments Due In Rolling Year Three
CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree
128000
CY2015Q1 us-gaap Fair Value Inputs Discount Rate
FairValueInputsDiscountRate
0.0883
CY2015Q1 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
46000
CY2015Q1 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
18200000
CY2015Q1 biol Litigation Settlement Amount Receivable Non Current
LitigationSettlementAmountReceivableNonCurrent
825000
CY2015Q1 biol Receivable For Legal Settlements On First Anniversary
ReceivableForLegalSettlementsOnFirstAnniversary
275000
CY2015Q1 biol Receivable For Legal Settlements On Second Anniversary
ReceivableForLegalSettlementsOnSecondAnniversary
275000
CY2015Q1 biol Receivable For Legal Settlements On Third Anniversary
ReceivableForLegalSettlementsOnThirdAnniversary
275000
CY2015Q1 biol Litigation Settlement Amount Receivable Current
LitigationSettlementAmountReceivableCurrent
550000
CY2015Q1 us-gaap Litigation Settlement Amount
LitigationSettlementAmount
1400000
CY2015Q1 biol Settlement Expense For Dismissal Of Patent Infringement Lawsuit Recovered
SettlementExpenseForDismissalOfPatentInfringementLawsuitRecovered
68000
CY2015Q1 biol Legal Settlement At Present Value
LegalSettlementAtPresentValue
1200000
CY2015Q1 us-gaap Loss Contingency Settlement Agreement Terms
LossContingencySettlementAgreementTerms
As part of the settlement, Fotona agreed to pay the Company a total of $1.4 million, with $550,000 payable within 10 days of March 24, 2015 and the remaining, $825,000 payable in three increments of $275,000 each to be paid no later than the first, second and third anniversary of the effective date of the agreement.
CY2015Q1 biol Entity Wide Revenue Major Customer Number
EntityWideRevenueMajorCustomerNumber
0
CY2014Q1 biol Entity Wide Revenue Major Customer Number
EntityWideRevenueMajorCustomerNumber
0
CY2015Q1 biol Entity Wide Accounts Receivable Major Customer Number
EntityWideAccountsReceivableMajorCustomerNumber
0
CY2014Q1 biol Entity Wide Accounts Receivable Major Customer Number
EntityWideAccountsReceivableMajorCustomerNumber
0
CY2015Q1 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2014Q1 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2015Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.009
CY2014Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.005
CY2015Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2014Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34

Files In Submission

Name View Source Status
0001564590-15-003181-index-headers.html Edgar Link pending
0001564590-15-003181-index.html Edgar Link pending
0001564590-15-003181.txt Edgar Link pending
0001564590-15-003181-xbrl.zip Edgar Link pending
biol-10q_20150331.htm Edgar Link pending
biol-20150331.xml Edgar Link completed
biol-20150331.xsd Edgar Link pending
biol-20150331_cal.xml Edgar Link unprocessable
biol-20150331_def.xml Edgar Link unprocessable
biol-20150331_lab.xml Edgar Link unprocessable
biol-20150331_pre.xml Edgar Link unprocessable
biol-ex101_20150331695.htm Edgar Link pending
biol-ex103_20150331707.htm Edgar Link pending
biol-ex311_201503319.htm Edgar Link pending
biol-ex312_201503317.htm Edgar Link pending
biol-ex321_201503316.htm Edgar Link pending
biol-ex322_201503318.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending